Kelun Pharma Holds Steady in China Mid‑Cap Pharma: Market Snapshot, Trading Dynamics & Strategic Outlook
Kelun Pharma stays flat but solid above its 200‑day MA, offering a resilient mid‑cap pharma stock with expanding R&D and supply‑chain resilience—ideal for cautious investors targeting China’s healthcare sector.
- SICHUAN KELUN PHARMACEUTIC
- China
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read